Clinical Trials Browser

Phase 1/2 × OTHER × Pancreatic Cancer Resectable × Clear all

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Cancer Resectable